R&D On the power of T-cells, with Cedrik Britten Dr Cedrik Britten, chief medical officer at Immatics, discusses novel PRAME-directed T-cell immunotherapies.
News GSK's pullback from cell therapy continues as Immatics allia... Immatics has become the latest partner for GSK in the area of cell therapy for cancer to see its alliance shelved, just two and a half years after being set up.
News GSK begins cancer cell therapy tie-up with Immatics Cancer biotech Immatics has begun a collaboration with GlaxoSmithKline to develop novel therapies built around its T-cell-based technology.
Views & Analysis European biotech round-up: Ablynx’s big break and more European biotech: a mixture of encouraging clinical trials and new funding lift the sector.
News Enhertu OK ends 10-year EU gap in frontline breast cancer Enhertu plus Perjeta has become the first new frontline therapy approved for advanced HER2-positive breast cancer in the EU for over a decade.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
